Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | CASP3 | P42574 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411616 | 0.87 | POLB (0.62) | MAOBMAOACA1CA2CA9 | |
| SCHEMBL1092244 | 0.87 | MGAT2 (0.65) | MAOBMAOACA1CA2CA9 | |
| SCHEMBL14111824 | 0.85 | SMN1; SMN2 (0.57) | CA1CA2CA9PKMMGAT2 | |
| SCHEMBL4904434 | 0.84 | ALDH1A1 (0.61) | MAOBMAOACASP3CYP19A1MGAT2 | |
| SCHEMBL5840708 | 0.78 | MAOB (0.56) | MAOBCA1CA2CA9PKM | |
| SCHEMBL17086317 | 0.77 | TP53 (0.53) | CA1CA2CA9PKMCYP19A1 | |
| SCHEMBL4905395 | 0.76 | TP53 (0.63) | CYP19A1MGAT2TP53MAPTLMNA | |
| SCHEMBL1091461 | 0.76 | CA12 (0.55) | MAOBMAOACASP3CA1CA2 | |
| SCHEMBL565842 | 0.75 | PTPN1 (0.48) | CA1CA2CA9CYP19A1MGAT2 | |
| SCHEMBL565841 | 0.75 | PTPN1 (0.48) | CA1CA2CA9CYP19A1MGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623906-B2 | Carboxy isatin hydrazones and their esters as Shp2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2010121212-A2 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034186-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER | PTPN1, PTPN2, PTPN7 | MAOB 3399/4885MAOA 3005/4885CASP3 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.